Learn about emerging clinical trial options for metastatic castration-resistant prostate cancer (mCRPC) in this fireside chat featuring Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN and Pedro Barata, MD, Director of the GU Medical Oncology Research Program at University Hospitals Seidman Cancer Center.

This discussion explores the Omaha-003 and Omaha-004 clinical trials, including how these investigational treatments work to block hormones that help prostate cancer grow, the differences between the studies, and who may qualify to participate.

Topics Covered:
• Overview of metastatic castration-resistant prostate cancer (mCRPC)
• How investigational hormone-blocking therapies work
• Key differences between the Omaha-003 and Omaha-004 clinical trials
• Eligibility criteria and what participation may involve
• The role of clinical trials in advanced prostate cancer treatment

Featured Speakers:
• Keith Crawford, MD, PhD — Director of Clinical Trials and Patient Education, PHEN
• Pedro Barata, MD — Director of the GU Medical Oncology Research Program, University Hospitals Seidman Cancer Center